These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
180 related articles for article (PubMed ID: 2193875)
21. Specificity of MOC-31 and HBME-1 immunohistochemistry in the differential diagnosis of adenocarcinoma and malignant mesothelioma: a study on environmental malignant mesothelioma cases from Turkish villages. Gümürdülü D; Zeren EH; Cagle PT; Kayasel uk F; Alparslan N; Kocabas A; Tuncer I Pathol Oncol Res; 2002; 8(3):188-93. PubMed ID: 12515999 [TBL] [Abstract][Full Text] [Related]
22. Malignant mesothelioma: ultrastructural distinction from adenocarcinoma. Warhol MJ; Hickey WF; Corson JM Am J Surg Pathol; 1982 Jun; 6(4):307-14. PubMed ID: 6287872 [TBL] [Abstract][Full Text] [Related]
23. Pleural mesothelioma of epithelial type and pulmonary adenocarcinoma: an ultrastructural and cytochemical comparison. Dewar A; Valente M; Ring NP; Corrin B J Pathol; 1987 Aug; 152(4):309-16. PubMed ID: 3668733 [TBL] [Abstract][Full Text] [Related]
24. Adenocarcinoma simulating mesothelioma: a clinicopathologic and immunohistochemical study of 29 cases. Koss MN; Fleming M; Przygodzki RM; Sherrod A; Travis W; Hochholzer L Ann Diagn Pathol; 1998 Apr; 2(2):93-102. PubMed ID: 9845725 [TBL] [Abstract][Full Text] [Related]
25. Immunohistochemical marker panels for distinguishing between epithelioid mesothelioma and lung adenocarcinoma. Kushitani K; Takeshima Y; Amatya VJ; Furonaka O; Sakatani A; Inai K Pathol Int; 2007 Apr; 57(4):190-9. PubMed ID: 17316414 [TBL] [Abstract][Full Text] [Related]
26. Calretinin, thrombomodulin, CEA, and CD15: a useful combination of immunohistochemical markers for differentiating pleural epithelial mesothelioma from peripheral pulmonary adenocarcinoma. Comin CE; Novelli L; Boddi V; Paglierani M; Dini S Hum Pathol; 2001 May; 32(5):529-36. PubMed ID: 11381372 [TBL] [Abstract][Full Text] [Related]
27. The value of ThinPrep and cytospin preparation in pleural effusion cytological diagnosis of mesothelioma and adenocarcinoma. Ylagan LR; Zhai J Diagn Cytopathol; 2005 Mar; 32(3):137-44. PubMed ID: 15690333 [TBL] [Abstract][Full Text] [Related]
29. The distinction of adenocarcinoma from malignant mesothelioma in cell blocks of effusions: the role of routine mucin histochemistry and immunohistochemical assessment of carcinoembryonic antigen, keratin proteins, epithelial membrane antigen, and milk fat globule-derived antigen. Cibas ES; Corson JM; Pinkus GS Hum Pathol; 1987 Jan; 18(1):67-74. PubMed ID: 2434407 [TBL] [Abstract][Full Text] [Related]
30. The cytologic diagnosis of mesothelioma. Ehya H Semin Diagn Pathol; 1986 Aug; 3(3):196-203. PubMed ID: 3616223 [TBL] [Abstract][Full Text] [Related]
31. Immunohistochemistry in the diagnosis of malignant mesothelioma. Pfaltz M; Odermatt B; Christen B; Rüttner JR Virchows Arch A Pathol Anat Histopathol; 1987; 411(4):387-93. PubMed ID: 2442887 [TBL] [Abstract][Full Text] [Related]
32. [Malignant mesothelioma of the pleura. Analysis of its immunohistochemical aspects]. Chenard-Neu MP; Bellocq JP; Maier A; Batzenschlager A Ann Pathol; 1990; 10(1):20-7. PubMed ID: 2328062 [TBL] [Abstract][Full Text] [Related]
33. Basal lamina reduplication in malignant epithelioid pleural mesothelioma. Di Muzio M; Spoletini L; Strizzi L; Procopio A; Tassi G; Casalini A; Modesti A Ultrastruct Pathol; 1998; 22(6):467-75. PubMed ID: 9891926 [TBL] [Abstract][Full Text] [Related]
34. Lymphohistiocytoid mesothelioma: a clinical, immunohistochemical and ultrastructural study of four cases and literature review. Yao DX; Shia J; Erlandson RA; Klimstra DS Ultrastruct Pathol; 2004; 28(4):213-28. PubMed ID: 15693633 [TBL] [Abstract][Full Text] [Related]
35. [Pleuropulmonary tumors. Presentation of 2 cases with peculiar clinicopathologic traits]. Esquius Soriguera J; Alejo Sánchez M; Padilla Navas I; Rodríguez Casquero C; León González C Rev Clin Esp; 1989 Oct; 185(6):303-5. PubMed ID: 2623239 [TBL] [Abstract][Full Text] [Related]
36. Expression of calretinin and other mesothelioma-related markers in thymic carcinoma and thymoma. Pan CC; Chen PC; Chou TY; Chiang H Hum Pathol; 2003 Nov; 34(11):1155-62. PubMed ID: 14652817 [TBL] [Abstract][Full Text] [Related]
37. The value of antibodies 44-3A6, SM3, HBME-1, and thrombomodulin in differentiating epithelial pleural mesothelioma from lung adenocarcinoma: a comparative study with other commonly used antibodies. Ordóñez NG Am J Surg Pathol; 1997 Dec; 21(12):1399-408. PubMed ID: 9414183 [TBL] [Abstract][Full Text] [Related]
38. Immunohistochemistry in the distinction between malignant mesothelioma and pulmonary adenocarcinoma: a critical evaluation of new antibodies. Abutaily AS; Addis BJ; Roche WR J Clin Pathol; 2002 Sep; 55(9):662-8. PubMed ID: 12194995 [TBL] [Abstract][Full Text] [Related]
39. Expression of "myelomonocytic" antigens in mesotheliomas and adenocarcinomas involving the serosal surfaces. Wick MR; Mills SE; Swanson PE Am J Clin Pathol; 1990 Jul; 94(1):18-26. PubMed ID: 1694390 [TBL] [Abstract][Full Text] [Related]